TARSONSTarsons Products Limited
Convert to ideaHealthcare · Medical Equipment
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.8 this quarter.
Momentum from moving averages, Supertrend and RSI.
4 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
4 found · risk watch
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹124 Cr | ₹-0 Cr | 2.29% | -0.27% | ₹-0.06 | 1.1x |
| Q1 FY2027 | ₹110 Cr | ₹-1 Cr | -0.94% | -1.31% | ₹-0.27 | 0.8x |
| Q4 FY2026 | ₹121 Cr | ₹4 Cr | 4.29% | 3.46% | ₹0.79 | 1.9x |
| Q3 FY2026 | ₹84 Cr | ₹7 Cr | 7.72% | 8.44% | ₹1.33 | 2.8x |
| Q2 FY2026 | ₹81 Cr | ₹7 Cr | 7.42% | 8.10% | ₹1.23 | 3.0x |
| Q1 FY2026 | ₹71 Cr | ₹4 Cr | 6.27% | 5.01% | ₹0.67 | 2.1x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Medical Equipment
Compare with peers →Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.